Traditionally, diagnostic imaging and in vitro diagnostics have lived on different planets. In vivo imaging is a capital equipment business, while in vitro diagnostic businesses are built on reagents and consumables. Imaging looks for morphological changes in the body; invitro diagnostics detect analytes and markers of disease in tissues and fluids. Even the customers are different. Imaging equipment companies target radiologists, in vitro diagnostics companies sell to laboratories. So why would imaging giant Siemens AG announce, at the end of April, that it will acquire traditional in vitro diagnostics firm Diagnostic Products Corp. for $1.86 billion? [See Deal]
In Vivo and In Vitro Diagnostics Converge: Siemens buys DPC
Why would imaging giant Siemens buy traditional in vitro diagnostics firm Diagnostic Products for $1.86 billion? Siemens has a mature imaging business, so the high growth opportunities in diagnostics, with their recurring revenue streams from consumables, look attractive. But more than that, it's becoming apparent that on the molecular level, in vivo imaging and in vitro diagnostics are converging.
More from Archive
• By
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
• By
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
• By
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.
In Partnership with Cerba Research
The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.
More from In Vivo
• By
Top 30 leaders: see the list of industry influencers highlighted in the sixth edition of In Vivo's Rising Leaders series.
• By
AI-related deal activitiy in the first quarter of 2025 was punctuated by a last-minute $600m raise for Isomorphic Labs.
• By
The process of manufacturing medicines can often be complex, expensive and harmful to the environment. Initiatives like RESILIENCE UK are seeking to simplify this process, utilizing VR technology to create a more sustainable learning environment for both students and companies.